EADV 2026: Lebrikizumab improved hand and foot clearance, itch, and pain at 16 weeks versus placebo in a phase 3b atopic dermatitis trial.
News|Poll|February 20, 2015
13-year-old With Hyperpigmented Rash
Author(s)ReelDx
This 13-year-old boy presents with hyperpigmented skin on his neck. He is 66.75 inches and weighs 232 pounds. Your suspicion?
Advertisement
This 13-year-old boy presents with hyperpigmented skin on his neck. He is 66.75 inches and weighs 232 pounds.
Your suspicion?
Advertisement
Related to this article
The FDA has approved baricitinib for adolescents aged 12 and older with severe alopecia areata, marking the first systemic oral therapy cleared for this population.
Takeda’s oral TYK2 inhibitor showed rapid skin clearance in phase 3 psoriasis trials as FDA fast-tracks review; decision expected early 2027.
Advertisement
Advertisement
Trending on Patient Care Online
1
FDA Grants Breakthrough Device Designation to Natera's Multi-Cancer Early Detection Blood Test
2
Who Should Get a CGM? Expanding the Primary Care Candidate Pool
3
Most Adolescents With Colorectal Cancer Diagnosed at Advanced Stage, Study Finds
4
PrEP Deserts: Why HIV Prevention Still Misses Those at Risk
5